Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ININmune Bio, Inc. logo

INmune Bio, Inc. (INMB)

NASDAQ Capital Market · Currency in USD
$1.46 ▼ -0.08 (-5.19%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.48 ▲ +0.02 (+1.37%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$1.54
Open
$1.49
Day's Range
$1.46 – $1.51
52 Week Range
$1.09 – $2.60
Volume
190,559
Avg. Volume
606,101
Market Cap
$40.52M
Beta (5Y Monthly)
0.90
PE Ratio (TTM)
--
EPS (TTM)
-$0.69
Earnings Date
Oct 29, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$22.00

Profile: INmune Bio, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
21
CEO
David J. Moss

INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases.

Earnings

Next report: Thu, Oct 29, 2026
EPS estimate -$0.15 · Revenue est. $1.88M
DateEst.Actual
Aug 6, 2026-$0.21-$0.05Beat
May 7, 2026-$0.25-$0.20Beat
Mar 30, 2026-$0.27-$0.18Beat
Oct 30, 2025-$0.31-$0.24Beat
Aug 7, 2025-$0.37-$1.05Miss
May 8, 2025-$0.43-$0.43Beat

Analyst view

Consensus price target
$22.00 ▲ +1,406.8%
Range $22.00 – $22.00
Rating: Buy
Buy 67% · Hold 22% · Sell 11%

Get free alerts on INMB and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.